Metoclopramide may be effective for clozapine-induced hypersalivation

ABSTRACT FROM: Kreinin A, Miodownik C, Mirkin V, et al. Double-blind randomized, placebo-controlled trial of metoclopramide for hypersalivation associated with clozapine. J Clin Psychopharmacol 2016;36:200–5. What is already known on this topic Clozapine-induced hypersalivation is the most prevalent adverse effect experienced by patients treated with clozapine and negatively impacts on quality of life,1 with symptoms particularly prevalent at night-time. Pharmacotherapeutic strategies employed to date, based on multiple mechanisms including antimuscarinic agents and α-2 agonists have largely been associated with, at most, a minimal therapeutic effect.2 The development of strategies would thus be welcomed given the lack of effective treatment options, with such strategies hopefully being associated with an improvement in clinical outcome and perhaps also long-term treatment adherence. Methods of the study A 3-week randomised double-blind trial of metoclopramide (n=30) compared with placebo (n=28) was conducted on inpatients between January 2012 and...

Source: Evidence-Based Mental Health - October 20, 2016 Category: Psychiatry & Psychology Authors: Hallahan, B. Tags: Clinical trials (epidemiology), Neurology, Schizophrenia spectrum, Epidemiology Pharmacological interventions Source Type: research